Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines

Lyon, France – May 17, 2022 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a preclinical evaluation combining …

Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology

Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Lyon, France – April 21, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today that the Phase 2a results for its broad-spectrum influenza vaccine candidate, OVX836, have been published under the title “Randomized, …

Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to its Board of Directors

Company also announces upcoming presentation of clinical data for its pan-influenza vaccine candidate at World Vaccine Congress  Lyon, France – April 14, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today the appointment of Dr. Michael Watson to its Board of Directors. Dr. Watson brings over 20 years …